HSA List of Notified Complementary Health Products

The List of Notified Complementary Health Products is a Health Sciences Authority (HSA) information list for complementary health products that companies have voluntarily notified to HSA. HSA's page states that the initiative began on 1 August 2022 and that products are added over time when companies self-assess against the relevant published requirements and supporting information. The page linked a downloadable list current as of 25 August 2026 and was last updated 26 August 2026 (HSA, accessed 27 August 2026).

What notification means

Notification is based on a company's voluntary declaration and self-assessment of relevant supporting information against applicable complementary-health-product guidelines. HSA expressly says that listing must not be misconstrued as HSA endorsement. The list therefore provides a way to identify products whose companies have made the relevant notification; it is not an HSA safety evaluation, product approval, licensing register, or guarantee that a product is suitable for a particular person (HSA, List of Notified Complementary Health Products, accessed 27 August 2026).

Relationship to health-supplement regulation

HSA explains that health supplements generally do not require pre-market approval, evaluation or licensing before local sale. Dealers—including manufacturers, importers, distributors and retailers—remain responsible for meeting HSA safety and quality standards. HSA prohibits medicinal ingredients such as steroids in health supplements, sets limits for toxic heavy metals, and expects product labels and advertisements not to make false, misleading, treatment or disease-prevention claims (HSA, How health supplements are regulated by HSA, 15 July 2026). The notification list is one voluntary safeguard or information channel within that wider regulatory approach; it does not replace dealer responsibility or turn a supplement into a medicine.

How to interpret an entry

A consumer checking the list should treat an entry as a dated notification record and read the product label, intended use, directions and warnings separately. Listed complementary health products are not intended to diagnose, treat, cure or prevent disease, according to HSA's list page (HSA, accessed 27 August 2026). Consumers should not infer clinical efficacy, universal safety, or personal suitability from inclusion. If a product appears to cause illness or side effects, HSA advises consulting a doctor and bringing the product along; HSA also conducts post-market surveillance, including market sampling and adverse-reaction monitoring (HSA, How health supplements are regulated by HSA, 15 July 2026). The notification process is based on the company's self-assessment of relevant supporting information against the published guidelines; HSA does not pre-approve each listed product (HSA, accessed 27 August 2026).